Consisting of human IgG4-Fc region of anti-PD-1 mAb and extracellular domain (ECD) of SIRPα, it achieves the synergistic anti-tumor effects by simultaneously activating both innate and acquired immune responses to suppress tumor immune escape and release immune suppression at immune checkpoints. This evidence concerns the gene SIRPA and neoplasm.